Clinical Trials
73 trialsToripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
PREVENT-2
Guangxi Medical University
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
CCGLC-012
Tongji Hospital
CCGLC-007
Tongji Hospital
OPTI-DOSE
University Medical Center Groningen
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
OPTIONS-05
Fudan University
CASTLE-09
Fudan University
CASTLE-10
Fudan University
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Sun Yat-sen University
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Second Affiliated Hospital of Guangzhou Medical University
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
Peking Union Medical College Hospital
CASTLE-08
Fudan University
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
Fudan University
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
Shandong New Time Pharmaceutical Co., LTD
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
Fudan University
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
Sun Yat-sen University
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
Sun Yat-sen University
LEADER-001
The First Hospital of Jilin University
Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Tianjin Medical University Cancer Institute and Hospital
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
Fudan University
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Fudan University
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
Shandong Public Health Clinical Center
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
Sir Salimullah Medical College Mitford Hospital
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
Sun Yat-sen University
iPLENTY-pvtt
RenJi Hospital
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
Chinese PLA General Hospital
sPLENTY-pc
RenJi Hospital
LENVOS
Centre Leon Berard
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
The First Affiliated Hospital with Nanjing Medical University
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
Henan Cancer Hospital
Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
Ruijin Hospital
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
The University of Hong Kong
Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
National University Hospital, Singapore
To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
Institute of Liver and Biliary Sciences, India
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital